

Abstract of the Disclosure

- 5 A conjugate of a toxin and a cytokine, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α , each optionally further comprising a radionuclide, are useful therapeutic reagents for treating leukemias and lymphomas.

08949758 101497